Tag: CohBar
May 3, 2019
CohBar to Resume its Phase 1a/1b Clinical Trial
CohBar (NASDAQ:CWBR) has announced it will be resuming its Phase 1a/1b clinical trial of CB4211 after concluding conversations with the...
December 2, 2018
5 Top Weekly NASDAQ Biotech Stocks: Arsanis Gains 271 Percent
Arsanis, Tyme Technologies, CohBar, Cocrystal Pharma and Contrafect were last week's top gainers. July 12, 2018
CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH
CohBar (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that it... April 19, 2018
CohBar Announces Voluntary Delisting from the TSX Venture Exchange
CohBar (NASDAQ:CWBR) and (TSXV:COB.U) today announced that it has applied to voluntarily delist its common shares from the TSX Venture...
April 13, 2017